Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
13.20
+0.01 (0.08%)
Nov 17, 2026, 3:04 PM CST
SHE:300497 Revenue
Jiangxi Fushine Pharmaceutical had revenue of 661.89M CNY in the quarter ending September 30, 2026, with 159.89% growth. This brings the company's total for the last twelve months to 1.97B, up 102.59% year-over-year. In the year 2025, Jiangxi Fushine Pharmaceutical had annual revenue of 1.18B with 0.61% growth. That makes Jiangxi Fushine Pharmaceutical the 14,702nd largest company in the world by revenue and 2,638th in China.
Revenue (ttm)
1.97B
Revenue Growth
+102.59%
P/S Ratio
3.61
Revenue / Employee
n/a
Employees
1,663
Market Cap
7.11B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:300497 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.18B | 7.14M | 0.61% |
| Dec 31, 2024 | 1.18B | -431.82M | -26.83% |
| Dec 31, 2023 | 1.61B | -37.59M | -2.28% |
| Jan 1, 2023 | 1.65B | 217.72M | 15.23% |
| Jan 1, 2022 | 1.43B | -63.41M | -4.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.13B |
| Novogene | 2.30B |
| Aurisco Pharmaceutical | 1.67B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.43B |
| Vcanbio Cell & Gene Engineering Corp., | 1.38B |
| Chengdu Easton Biopharmaceuticals | 1.30B |
| Bio-Thera Solutions | 1.05B |
| Daan Gene | 776.43M |